Lentiviral Vector Packaging Efficiency via Cis-Acting Elements
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy vectors for treating disorders associated with a defective human β-globin gene face challenges such as low production rates, high production costs, and inefficient gene expression, particularly in hematopoietic stem cells, which limits their clinical efficacy for inherited anemias like thalassemia.
Innovation Solution
A lentiviral vector comprising a human β-globin gene, upstream locus control region, cis-acting posttranscriptional regulatory elements, and a self-inactivating retroviral LTR, optimized with elements like WPRE and SV40 polyadenylation signals, is used to enhance vector integration and expression in hematopoietic stem cells, potentially offering a cure for thalassemia through autologous stem cell therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current gene therapy vectors are used to treat inherited anemias, then gene delivery can be achieved, but production rates are low and production costs are high
Solution Approach 1:
The patent modifies key parameters of the vector system by incorporating specific regulatory elements (WPRE, SV40 polyadenylation signals, locus control regions) that fundamentally change the expression and packaging efficiency parameters, thereby increasing production rates and reducing costs
2Reliability
If current gene therapy vectors are used, then gene delivery is possible, but gene expression efficiency in hematopoietic stem cells is insufficient
Solution Approach 1:
The patent creates a composite vector structure combining multiple regulatory elements (LCR, WPRE, SV40 polyA signals, cis-acting posttranscriptional elements) that work synergistically to enhance gene expression efficiency and clinical efficacy in hematopoietic stem cells
3Ease of operation
If traditional viral vectors are used for gene therapy, then gene delivery can be achieved, but immunogenicity is high
Solution Approach 1:
The patent extracts and removes immunogenic components from the viral vector system while retaining the essential gene delivery capability, using a modified lentiviral vector structure that reduces immune recognition and response
Data Source
AI summary
Disclosed herein are gene therapy vectors used for efficiently transducing cells to express a human β-globin gene. Specifically disclosed is an expression vector which comprises: an expression cassette for a β-globin gene, which comprises exons and introns of human β-globin gene, as well as cis-acting elements including one or more of WPRE, SV40 polyadenylation signal and/or SV40 ori. The disclosed expression vectors have significantly enhanced viral vector packaging efficiency in viral vector packaging cell lines, which leads to effective integration of lentiviral vectors and high expression level of β-globin gene in target cells. Also disclosed are pharmaceutical compositions and therapeutic methods utilizing such expression vectors.